Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolvaptan effects on renal water and sodium handling in autosomal dominant polycystic kidney disease
2014-001973-15Phase 2Completed
- Sponsor
- University Clinic in Nephrology and Hypertension, Department of Medical Research
- Start
- Jun 2014
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of tolvaptan and octreotide in autosomal dominant polycystic kidney disease (ADPKD) (2 arms), sponsored by University Clinic in Nephrology and Hypertension, Department of Medical Research. Primary endpoint: Free water clearance. Started Jun 2014; status: completed.
02
Drugs
tolvaptanoctreotide
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on 2014-001973-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-001973-15.